Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2018. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific transaction involving American Depositary Shares (ADSs).
| Metric | Value |
|---|---|
| Instrument | American Depositary Shares (ADSs) |
| Transaction Type | Acquisition via dividend reinvestment |
| Transaction Date | April 12, 2018 |
| Transaction Price | $40.62 per ADS |
| Total Volume | 518.406 ADSs |
| Exchange | New York Stock Exchange (XYNS) |
Material Changes
The filing does not contain comparative financial data or material changes to the company's overall financial position versus prior periods. It details a routine acquisition of ADSs by Mr. D E Troy (SVP & General Counsel) following the reinvestment of dividends paid on April 12, 2018, under the Company's US Deferred Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a statutory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- The transaction was an acquisition of 518.406 ADSs by Mr. D E Troy.
- The acquisition resulted from the automatic reinvestment of dividends paid on April 12, 2018.
- The transaction price was fixed at $40.62 per ADS.
- The filing does not reflect any change in the company's operational or financial performance.